Stocks and Investing
Stocks and Investing
Mon, January 22, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Charles Duncan Reiterated (AXSM) at Buy and Held Target at $108 on, Jan 22nd, 2024
Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $108 on, Jan 22nd, 2024.
Charles has made no other calls on AXSM in the last 4 months.
There are 4 other peers that have a rating on AXSM. Out of the 4 peers that are also analyzing AXSM, 0 agree with Charles's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Charles
- David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $113 on, Tuesday, January 16th, 2024
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Tuesday, December 26th, 2023
- David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $125 on, Wednesday, December 13th, 2023
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $100 on, Monday, September 25th, 2023
Contributing Sources